| Identification | Back Directory | [Name]
ROKITAMYCIN | [CAS]
74014-51-0 | [Synonyms]
M-19-Q
Rokital
TMS 19Q
Rikamycin
Ricamycin
ROKITAMYCIN
T'urimyein H4
ROKITAMYCIN USP/EP/BP
3''-Propionylleucomycin A5
Leummycin V 4B-bu-tanoate 3 B-propanoate
Leucomycin V, 4B-butanoate 3B-propanoate
Leucomycin V, 4B-butanoate 3B-propanoate (9CI) | [Molecular Formula]
C42H69NO15 | [MDL Number]
MFCD00941397 | [MOL File]
74014-51-0.mol | [Molecular Weight]
827.99 |
| Chemical Properties | Back Directory | [Melting point ]
116° | [alpha ]
D20 -71° (c = 1.0 in chloroform) | [Boiling point ]
879.3±65.0 °C(Predicted) | [density ]
1.21±0.1 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,Store in freezer, under -20°C | [pka]
13.06±0.70(Predicted) | [CAS DataBase Reference]
74014-51-0 |
| Hazard Information | Back Directory | [Description]
Rokitamycin is a semisynthetic macrolide
antibiotic, closely related to miokamycin(2) both in structure and antimicrobial spectrum. | [Originator]
Toyo Jozo (Japan) | [Definition]
ChEBI: Rokitamycin is an organic molecular entity. | [Brand name]
RICAMYCIN | [Pharmaceutical Applications]
3″-Propionyl leucomycin A5. A semisynthetic macrolide. Unstable in acid media.
The antibacterial spectrum is identical to that of erythromycin, but it is less active against Gram-positive cocci. It is poorly active against H. influenzae (MIC50 8 mg/L) and Mor. catarrhalis (MIC50 4 mg/L). It displays good activity against Campylobacter spp. (MIC50 0.1 mg/L), L. pneumophila (MIC50 0.1 mg/L) and M. pneumoniae (MIC50 0.003 mg/L). It is active against anaerobes, including some Bacteroides spp. (MIC50 <0.05 mg/L).
After a single oral dose of 600 mg, the peak plasma concentration was 1.9 mg/L after 0.6 h. Oral doses of 5, 10 and 15 mg/kg of a syrup formulation given to children achieved plasma concentrations of 0.26, 0.55 and 0.79 mg/L, respectively, after about 40 min. The half-life is around 2 h.
It is mainly eliminated in the bile; only about 2% appears in the urine. Its major metabolites are leucomycin A7, 10″-OH-rokitamycin (which show some antibacterial activity) and leucomycin V. In healthy adult volunteers, the proportions of rokitamycin and its metabolites in serum 30 min after a single oral dose of 1200 mg were 18% (leucomycin A7), 33% (10″-OH-rokitamycin) and 9% (leucomycin V). The pharmacokinetic behavior is not altered in patients with liver cirrhosis. It is available in Italy and Japan. |
|
| Company Name: |
CHEMSWORTH
|
| Tel: |
+91-261-2397244 |
| Website: |
www.chemsworth.com |
| Company Name: |
Matrix Scientific
|
| Tel: |
803 788-9494 All other calls |
| Website: |
www.matrixscientific.com |
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
| Company Name: |
MOLEKULA Ltd.
|
| Tel: |
+44 (0) 1747 831066 |
| Website: |
www.molekula.co.uk |
|